Fig. 6

CD8+ TIL densities as a measure of durvalumab pharmacodynamic activity in clinical trial NCT01693562. Enumeration of CD8+ TILs by image analysis was performed on matched sets of pretreatment and on-therapy (±6 weeks) specimens of 25 NSCLC patients. Tumor was manually annotated by a pathologist. The density of CD8+ TILs in paired sets was compared using a two-sided paired t test. Of 25 patients, 20 had increased CD8+ TILs during therapy, with an average increase of 365 cells/mm² (P = 0.009, 95% confidence interval = 101.3–628.5)